EARLIER: Leerink Boosts Intuitive Surgical Price Target 32%
Leerink boosted the price target for shares of Intuitive Surgical (NASDAQ: ISRG) from $420 to $555.
Analyst Richard Newitter is bullish on “ISRG's gen surgery penetration prospects (particularly Colorectal) in light of positive feedback on the just-released Xi system.”
Newitter's price target bump is on “now higher 2015 estimates and assuming ISRG sustains a premium valuation vs large-cap MedTech given a monopoly position in robotics.”
“Xi has potential to help re-accelerate system sales growth in 2015 and beyond and to drive higher da Vinci penetration in complex cases -- most notably in colorectal surgery,” according to the analyst.
Newitter lays out two points for investors to focus on going forward on Xi:
- ”Whether Xi and new features in the works (like advanced single-site) are “must-haves” that will inevitably prompt a widespread replacement cycle.”
- ”The extent to which multi-quadrant surgery and the promise of more advanced single-site capabilities will drive penetration into other gen surgery areas.”
The stock finished down 1.45 percent to $489.84 in Tuesday's trading.
Latest Ratings for ISRG
|Jan 2017||Evercore ISI Group||Downgrades||Buy||Hold|
|Oct 2016||Wells Fargo||Initiates Coverage On||Outperform|
|Aug 2016||Raymond James||Initiates Coverage on||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.